Mirum Pharmaceuticals, Inc. (MIRM)

Market Cap	6.18B +177.9%
Revenue (ttm)	471.79M +53.7%
Net Income	-41.42M
EPS	-0.84
Shares Out	59.88M
PE Ratio	n/a
Forward PE	917.51
Dividend	n/a
Ex-Dividend Date	n/a

Volume	805,332
Open	102.85
Previous Close	102.92
Day's Range	100.62 - 103.72
52-Week Range	36.88 - 103.81
Beta	0.49
Analysts	Strong Buy
Price Target	102.64 (-0.56%)
Earnings Date	Feb 25, 2026

About MIRM

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is ap...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 18, 2019
• Employees: 355
• Stock Exchange: NASDAQ
• Ticker Symbol: MIRM
• Website: https://www.mirumpharma.com

Financial Performance

In 2024, Mirum Pharmaceuticals's revenue was $336.89 million, an increase of 80.76% compared to the previous year's $186.37 million. Losses were -$87.94 million, -46.18% less than in 2023.

Analyst Summary

According to 11 analysts, the average rating for MIRM stock is "Strong Buy." The 12-month stock price target is $102.64, which is a decrease of -0.56% from the latest price.

Price Target

$102.64

(-0.56% downside)

Analyst Consensus: Strong Buy